A neonate is evaluated for ambiguous genitalia, presents with signs of adrenal insufficiency and salt loss. Laboratory results reveal increased 17-hydroxyprogesterone and decreased cortisol. Which enzyme deficiency best explains these findings?
সমাধান
সঠিক উত্তর: Option C
- The neonate described in the question presents with ambiguous genitalia, signs of adrenal insufficiency, salt loss, increased 17-hydroxyprogesterone, and decreased cortisol.
- These features are classic for a diagnosis of 21-hydroxylase deficiency, the most common form of congenital adrenal hyperplasia (CAH).
- 21-hydroxylase deficiency leads to impaired conversion of 17-hydroxyprogesterone to 11-deoxycortisol, resulting in decreased cortisol synthesis. This causes a loss of negative feedback on the pituitary gland, leading to increased ACTH secretion and adrenal hyperplasia.
- Because 21-hydroxylase is also required for aldosterone synthesis, its deficiency causes aldosterone deficiency, leading to salt wasting (hyponatremia, hyperkalemia, and volume depletion).
- The accumulation of 17-hydroxyprogesterone and its shunting into androgen pathways causes androgen excess, which results in virilization/ambiguous genitalia in genetic females.
This enzyme deficiency manifests with the triad of:
- Decreased cortisol
- Decreased aldosterone (leading to salt loss)
- Increased androgen production, causing ambiguous genitalia.
Why other options are incorrect:
- 11β-hydroxylase deficiency: Causes decreased cortisol but increased 11-deoxycorticosterone, which has mineralocorticoid activity, leading to hypertension instead of salt wasting.
- 17α-hydroxylase deficiency: Results in decreased sex steroids and cortisol but increased mineralocorticoids, causing hypertension and sexual infantilism, not ambiguous genitalia or salt loss.
- 3β-hydroxysteroid dehydrogenase deficiency: Leads to decreased cortisol, aldosterone, and androgens, but does not typically cause increased 17-hydroxyprogesterone or prominent androgen excess/ambiguous genitalia.
Summary: The key diagnostic clues are increased 17-hydroxyprogesterone, decreased cortisol, salt wasting, and ambiguous genitalia, all strongly indicating 21-hydroxylase deficiency.
Reference: Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 13th Edition, Volume II, Chapter on Adrenal Cortex Disorders, p. 1150–1160
- These features are classic for a diagnosis of 21-hydroxylase deficiency, the most common form of congenital adrenal hyperplasia (CAH).
- 21-hydroxylase deficiency leads to impaired conversion of 17-hydroxyprogesterone to 11-deoxycortisol, resulting in decreased cortisol synthesis. This causes a loss of negative feedback on the pituitary gland, leading to increased ACTH secretion and adrenal hyperplasia.
- Because 21-hydroxylase is also required for aldosterone synthesis, its deficiency causes aldosterone deficiency, leading to salt wasting (hyponatremia, hyperkalemia, and volume depletion).
- The accumulation of 17-hydroxyprogesterone and its shunting into androgen pathways causes androgen excess, which results in virilization/ambiguous genitalia in genetic females.
This enzyme deficiency manifests with the triad of:
- Decreased cortisol
- Decreased aldosterone (leading to salt loss)
- Increased androgen production, causing ambiguous genitalia.
Why other options are incorrect:
- 11β-hydroxylase deficiency: Causes decreased cortisol but increased 11-deoxycorticosterone, which has mineralocorticoid activity, leading to hypertension instead of salt wasting.
- 17α-hydroxylase deficiency: Results in decreased sex steroids and cortisol but increased mineralocorticoids, causing hypertension and sexual infantilism, not ambiguous genitalia or salt loss.
- 3β-hydroxysteroid dehydrogenase deficiency: Leads to decreased cortisol, aldosterone, and androgens, but does not typically cause increased 17-hydroxyprogesterone or prominent androgen excess/ambiguous genitalia.
Summary: The key diagnostic clues are increased 17-hydroxyprogesterone, decreased cortisol, salt wasting, and ambiguous genitalia, all strongly indicating 21-hydroxylase deficiency.
Reference: Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 13th Edition, Volume II, Chapter on Adrenal Cortex Disorders, p. 1150–1160